1. Japan Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
Rohto Pharmaceutical Co., Ltd.

Rohto Pharmaceutical Co., Ltd.

15.90
EUR
-0.20
(-1.24%)
2.89BMarket Cap
Nov 12Next Earn
Rohto Pharmaceutical Co., Ltd.
DUS:UC1
(Dusseldorf Stock Exchange)

Recent

price

15.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
490.13
512.07
547.1
621.2
669.64
732.27
679.04
754.04
805.9
825.92
793.6
875.1
1,046.13
1,187.25
1,354.78
1,521.15
- -
Revenue per Share
33.87
34.8
34.39
38.57
38.03
40.02
43.97
40.77
43
67.56
73.39
92.61
115.62
135.61
135.38
151.56
- -
Basic EPS, GAAP
17.6
7.27
48.04
51.53
31.48
29
41.5
60.14
65.06
55.27
42.54
69.79
92.12
111.05
115.7
95.31
- -
Free Cash Flow per Basic Share
7
8
8
9.12
9.03
10.02
10.01
11
11
13.5
13
15
20.5
24
31.04
41
- -
Dividend per Share
330.29
354.42
397.35
433.25
484.58
487.09
517.93
560.41
575.89
610.51
683.38
781.97
918.6
1,079.71
1,165.54
1,335.72
- -
Book Value per Share
319.69
344.75
388.81
420.78
465.32
471.7
506.24
542.38
560.25
588.02
648.78
740.15
876.69
1,039.31
850.3
964.43
- -
Tangible Book Value per Share
235
235
235
232
227
227
228
228
228
228
228
228
228
228
228
226
226
Basic Weighted Avg Shares
115,262
120,423
128,666
144,082
151,994
166,477
154,599
171,795
183,672
188,375
181,053
199,646
238,664
270,840
308,625
343,725
- -
Sales/Revenue/Turnover
20.64
11.32
11.18
11.68
8.66
9.42
10
11.11
11.33
11.98
12.7
14.54
14.23
14.79
12.39
11.96
- -
Operating Margin (%)
4,461
5,136
5,448
5,926
6,341
6,448
5,923
5,914
6,404
6,937
6,748
7,689
7,801
8,687
13,301
17,377
- -
Depreciation Expense
7,966
8,184
8,087
8,947
8,631
9,098
10,011
9,289
9,799
15,410
16,743
21,127
26,377
30,936
30,841
34,247
- -
Net Income, GAAP
40.9
42.19
40.56
38.71
37.26
36.47
32.12
44.49
39.76
29.67
27.11
23.99
22.92
24.38
26.82
26.49
- -
Effective Tax Rate (%)
6.91
6.8
6.29
6.21
5.68
5.47
6.48
5.41
5.34
8.18
9.25
10.58
11.05
11.42
9.99
9.96
- -
Profit Margin (%)
23,359
26,345
27,913
26,338
36,085
42,395
47,526
48,718
55,642
68,589
76,600
92,818
110,084
127,672
123,271
121,925
- -
Working Capital
2,716
3,335
1,578
1,666
1,074
994
1,765
1,702
1,424
5,190
5,787
13,350
7,516
5,190
50,374
35,502
- -
LT Debt
77,911
83,624
93,769
98,626
110,513
111,268
118,435
128,437
132,187
140,030
156,611
183,992
215,076
247,033
280,734
320,172
- -
Total Equity
8.98
8.6
8.54
9.53
7.05
8.18
8.47
7.98
8.94
11.02
10.35
11.63
11.86
12.18
9.18
8.25
- -
Return on Invested Capital (%)
9.91
9.5
8.48
8.64
7.69
7.79
8.41
7.23
7.27
10.98
10.78
11.49
12.27
12.65
10.72
9.75
- -
Return on Capital (%)
10.53
10.17
9.15
9.33
8.29
8.24
8.75
7.56
7.57
11.39
11.34
12.64
13.6
13.57
12.1
12.12
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
20,142
24,742
- -
LT Borrowings
26,939
28,188
- -
LT Finance Leases
- -
7,314
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
226
226
226
Market Capitalization
556,772
530,538
532,990

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
222,228
239,274
- -
Cash, Cash Equivalents & STI
78,244
86,816
- -
Accounts Receivable, Net
48,816
52,684
- -
Inventories
63,120
65,677
- -
Total Current Liabilities
102,277
117,349
- -
Payables & Accruals
- -
- -
- -
ST Debt
20,142
24,742
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.25%
15.38%
14.05%
Free Cash Flow
16.09%
20.47%
-18.28%
Net Income, GAAP
15.33%
15.81%
11.04%
Sales/Revenue/Turnover
7.82%
13.72%
11.37%
Total Cash Common Dividend
- -
25.86%
31%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
308,625
2026
- -
- -
- -
- -
343,725
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
135.38
2026
- -
- -
- -
- -
151.56
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
31.04
2026
- -
- -
- -
- -
41
2027
- -
- -
- -
- -
- -
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide; its core offerings include eye care products such as eye drops, contact lens care solutions, and eyewash; skin care items comprising face washes, lotions, creams, lip balms, sunscreens, and functional cosmetics; internal medicines like digestive aids and herbal remedies; over-the-counter pharmaceuticals encompassing ophthalmic, dermatological, gastrointestinal, and diagnostic drugs as well as Chinese herbal medicines and supplements; oral care products including toothpaste and mouthwashes; and additional services such as beauty counters for health consultations, diagnostic reagents, investment management, and contract development and manufacturing. The company operates primarily in the over-the-counter pharmaceuticals, consumer healthcare, and cosmetics segments, targeting consumers seeking health and beauty solutions, with a strong presence in Japan and international markets across Asia, North America, Europe, and beyond through subsidiaries and production facilities in the US, UK, China, Vietnam, Hong Kong, and Indonesia. Founded in 1899 as Shintendo Yamada Anmin Pharmacy and incorporated in 1949 with its current name, Rohto Pharmaceutical is headquartered in Ikuno-ku, Osaka, Japan, and lists on the Tokyo Stock Exchange Prime Market. Recent developments include the completion of its acquisition of Eu Yan Sang, a health and wellness platform, from Righteous Crane Holding in partnership with Mitsui in 2025 to bolster its natural health offerings; the acquisition of an additional 51% stake in Mono chem-pharm Produkte GmbH, an Austrian eye care firm, for 30 million euros in June 2024 to expand into Europe; and the purchase of Obagi trademark rights in Japan from Waldencast plc for $82.5 million in November 2025 to strengthen its skincare portfolio.